| Year |
Citation |
Score |
| 2023 |
Gumbo T, Srivastava S, Deshpande D, Pasipanodya JG, Berg A, Romero K, Hermann D, Hanna D. Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development. The Journal of Antimicrobial Chemotherapy. PMID 36794692 DOI: 10.1093/jac/dkad029 |
0.416 |
|
| 2022 |
Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T. Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy. Frontiers in Pharmacology. 13: 1024608. PMID 36330086 DOI: 10.3389/fphar.2022.1024608 |
0.307 |
|
| 2022 |
Heysell SK, Mpagama SG, Ogarkov OB, Conaway M, Ahmed S, Zhdanova S, Pholwat S, Alshaer MH, Chongolo AM, Mujaga B, Sariko M, Saba S, Rahman SMM, Uddin MKM, Suzdalnitsky A, ... ... Pasipanodya JG, et al. Pharmacokinetic-pharmacodynamic determinants of clinical outcomes for rifampin-resistant tuberculosis: a multi-site prospective cohort study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 35731948 DOI: 10.1093/cid/ciac511 |
0.369 |
|
| 2021 |
Srivastava S, Pasipanodya JG, Heysell SK, Boorgula GD, Gumbo T, McShane PJ, Philley JV. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease. Journal of Global Antimicrobial Resistance. PMID 34933140 DOI: 10.1016/j.jgar.2021.12.010 |
0.328 |
|
| 2021 |
Magombedze G, Pasipanodya JG, Gumbo T. Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. Communications Biology. 4: 664. PMID 34079045 DOI: 10.1038/s42003-021-02184-0 |
0.364 |
|
| 2020 |
Allwood BW, van der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, Evans CA, Evans D, Gray DM, Hoddinott G, Ivanova O, Jones R, Makanda G, Marx FM, Meghji J, ... ... Pasipanodya JG, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 24: 820-828. PMID 32912387 DOI: 10.5588/ijtld.20.0067 |
0.435 |
|
| 2020 |
Zentner I, Back HM, Kagan L, Subbian S, Nagajyothi J, Srivastava S, Pasipanodya J, Gumbo T, Bisson GP, Vinnard C. Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study. Frontiers in Pharmacology. 11: 1103. PMID 32848735 DOI: 10.3389/Fphar.2020.01103 |
0.438 |
|
| 2020 |
Sibandze DB, Magazi BT, Malinga LA, Maningi NE, Shey BA, Pasipanodya JG, Mbelle NN. Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis. Bmc Infectious Diseases. 20: 556. PMID 32736602 DOI: 10.1186/s12879-020-05256-4 |
0.456 |
|
| 2019 |
Pasipanodya JG, Gumbo T. Dosing tuberculosis drugs in young children: the road ahead. The Lancet. Child & Adolescent Health. PMID 31324599 DOI: 10.1016/S2352-4642(19)30180-4 |
0.42 |
|
| 2019 |
Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C. Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. The Journal of Antimicrobial Chemotherapy. PMID 31273386 DOI: 10.1093/Jac/Dkz265 |
0.408 |
|
| 2019 |
Dheda K, Lenders L, Srivastava S, Magombedze G, Wainwright H, Raj P, Bush SJ, Pollara G, Steyn R, Davids M, Pooran A, Pennel T, Linegar A, McNerney R, Moodley L, ... Pasipanodya JG, et al. Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. American Journal of Respiratory and Critical Care Medicine. PMID 30694692 DOI: 10.1164/Rccm.201807-1361Oc |
0.451 |
|
| 2018 |
Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T. Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. The Journal of Infectious Diseases. PMID 30597040 DOI: 10.1093/Infdis/Jiy587 |
0.486 |
|
| 2018 |
Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T. Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S349-S358. PMID 30496464 DOI: 10.1093/Cid/Ciy623 |
0.383 |
|
| 2018 |
Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S293-S302. PMID 30496461 DOI: 10.1093/Cid/Ciy611 |
0.48 |
|
| 2018 |
Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S274-S283. PMID 30496459 DOI: 10.1093/Cid/Ciy618 |
0.528 |
|
| 2018 |
Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T. Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S284-S292. PMID 30496458 DOI: 10.1093/Cid/Ciy610 |
0.543 |
|
| 2018 |
Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S317-S326. PMID 30496457 DOI: 10.1093/Cid/Ciy609 |
0.484 |
|
| 2018 |
Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, et al. Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients. American Journal of Respiratory and Critical Care Medicine. PMID 29877726 DOI: 10.1164/Rccm.201711-2333Oc |
0.456 |
|
| 2018 |
Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC. Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29697766 DOI: 10.1093/Cid/Ciy346 |
0.42 |
|
| 2018 |
Pasipanodya JG, Gumbo T. Individualizing Tuberculosis Treatment: Are Tuberculosis Programs In High Burden Settings Ready For Prime Time Therapeutic Drug Monitoring? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29514180 DOI: 10.1093/Cid/Ciy184 |
0.498 |
|
| 2017 |
Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C. Urine Colorimetry for Therapeutic Drug Monitoring of Pyrazinamide during Tuberculosis Treatment. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. PMID 29253711 DOI: 10.1016/J.Ijid.2017.12.017 |
0.486 |
|
| 2017 |
Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, Lee PS, Pasipanodya JG, Dheda K, Gumbo T. On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 29180526 DOI: 10.1128/Aac.02232-17 |
0.49 |
|
| 2017 |
Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP. Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. Plos One. 12: e0187624. PMID 29095954 DOI: 10.1371/Journal.Pone.0187624 |
0.409 |
|
| 2017 |
Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. The Journal of Antimicrobial Chemotherapy. 72: i3-i19. PMID 28922813 DOI: 10.1093/Jac/Dkx311 |
0.398 |
|
| 2017 |
Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease. The Journal of Antimicrobial Chemotherapy. 72: i48-i53. PMID 28922809 DOI: 10.1093/Jac/Dkx307 |
0.416 |
|
| 2017 |
Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, Gumbo T. The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent. The Journal of Antimicrobial Chemotherapy. 72: i36-i42. PMID 28922808 DOI: 10.1093/Jac/Dkx306 |
0.392 |
|
| 2017 |
Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. The Journal of Antimicrobial Chemotherapy. 72: i30-i35. PMID 28922807 DOI: 10.1093/Jac/Dkx305 |
0.395 |
|
| 2017 |
Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T. Linezolid as treatment for pulmonary Mycobacterium avium disease. The Journal of Antimicrobial Chemotherapy. 72: i24-i29. PMID 28922806 DOI: 10.1093/Jac/Dkx304 |
0.425 |
|
| 2017 |
Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrobial Agents and Chemotherapy. PMID 28807911 DOI: 10.1128/Aac.01206-17 |
0.38 |
|
| 2017 |
Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, Wakeland E, Deshpande D, Gumbo T. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 28584143 DOI: 10.1128/Aac.00751-17 |
0.397 |
|
| 2017 |
Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP. Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. The Journal of Antimicrobial Chemotherapy. PMID 28472448 DOI: 10.1093/Jac/Dkx111 |
0.417 |
|
| 2017 |
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, ... ... Pasipanodya JG, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet. Respiratory Medicine. PMID 28344011 DOI: 10.1016/S2213-2600(17)30079-6 |
0.532 |
|
| 2017 |
Rockwood N N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ. Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 28205671 DOI: 10.1093/Cid/Cix158 |
0.404 |
|
| 2017 |
Magazi BT, Khan S, Dlamini S, Pasipanodya J. Molecular characterization and antimicrobial susceptibility of
extended-spectrum b-lactamases (ESBL) producing enterobactericiaceae (ESBLPE) causing urinary tract infections (UTI): Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010–2015, South Africa Open Forum Infectious Diseases. 4: S590-S591. DOI: 10.1093/Ofid/Ofx163.1549 |
0.307 |
|
| 2016 |
Vinnard C, King L, Munsiff S, Crossa A, Iwata K, Pasipanodya J, Proops D, Ahuja S. The Long-Term Mortality of Tuberculosis Meningitis Patients in New York City: A Cohort Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 27927856 DOI: 10.1093/Cid/Ciw763 |
0.464 |
|
| 2016 |
Vinnard C, Ravimohan S, Tamuhla N, Ivaturi V, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP. Isoniazid clearance is impaired among HIV/tuberculosis patients with high levels of immune activation. British Journal of Clinical Pharmacology. PMID 27792837 DOI: 10.1111/Bcp.13172 |
0.414 |
|
| 2016 |
Srivastava S, Deshpande D, Pasipanodya J, Nuermberger E, Swaminathan S, Gumbo T. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S102-S109. PMID 27742641 DOI: 10.1093/Cid/Ciw483 |
0.403 |
|
| 2016 |
Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S95-S101. PMID 27742640 DOI: 10.1093/Cid/Ciw474 |
0.464 |
|
| 2016 |
Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S88-S94. PMID 27742639 DOI: 10.1093/Cid/Ciw473 |
0.508 |
|
| 2016 |
Deshpande D, Srivastava S, Pasipanodya JG, Bush SJ, Nuermberger E, Swaminathan S, Gumbo T. Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S80-S87. PMID 27742638 DOI: 10.1093/Cid/Ciw482 |
0.384 |
|
| 2016 |
Srivastava S, Deshpande D, Pasipanodya JG, Thomas T, Swaminathan S, Nuermberger E, Gumbo T. A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S75-S79. PMID 27742637 DOI: 10.1093/Cid/Ciw472 |
0.407 |
|
| 2016 |
Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S63-S74. PMID 27742636 DOI: 10.1093/Cid/Ciw471 |
0.416 |
|
| 2016 |
Modongo C, Pasipanodya JG, Magazi BT, Srivastava S, Zetola NM, Williams SM, Sirugo G, Gumbo T. Artificial intelligence and amikacin exposures predictive of outcome in multidrug-resistant tuberculosis patients. Antimicrobial Agents and Chemotherapy. PMID 27458224 DOI: 10.1128/Aac.00962-16 |
0.457 |
|
| 2016 |
Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Pulmonary Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. PMID 27458221 DOI: 10.1128/Aac.00990-16 |
0.412 |
|
| 2016 |
Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T. Amikacin optimal exposures targets in the hollow fiber system model of tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 27458215 DOI: 10.1128/Aac.00961-16 |
0.453 |
|
| 2016 |
Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C. Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. Bmc Infectious Diseases. 16: 242. PMID 27250739 DOI: 10.1186/S12879-016-1576-1 |
0.398 |
|
| 2016 |
Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE, Cirrincione KN, Sherman CM, Swaminathan S, Gumbo T. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. Ebiomedicine. 6: 126-38. PMID 27211555 DOI: 10.1016/J.Ebiom.2016.02.040 |
0.527 |
|
| 2016 |
Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. Antimicrobial Agents and Chemotherapy. PMID 27067317 DOI: 10.1128/Aac.02821-15 |
0.356 |
|
| 2016 |
Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. Antimicrobial Agents and Chemotherapy. 60: 2895-900. PMID 26926649 DOI: 10.1128/Aac.03112-15 |
0.398 |
|
| 2016 |
Deshpande D, Pasipanodya JG, Gumbo T. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. Antimicrobial Agents and Chemotherapy. 60: 2157-63. PMID 26810646 DOI: 10.1128/Aac.02854-15 |
0.366 |
|
| 2015 |
Shenje J, Ifeoma Adimora-Nweke F, Ross IL, Ntsekhe M, Wiesner L, Deffur A, McIlleron HM, Pasipanodya J, Gumbo T, Mayosi BM. Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. Ebiomedicine. 2: 1640-9. PMID 26870790 DOI: 10.1016/J.Ebiom.2015.09.025 |
0.418 |
|
| 2015 |
Ferro BE, Srivastava S, Deshpande D, Sherman CM, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. Cuddling Nightmare Bacteria: Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow Fiber Mycobacterium abscessus Disease Model. Antimicrobial Agents and Chemotherapy. PMID 26643339 DOI: 10.1128/Aac.02282-15 |
0.406 |
|
| 2015 |
Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 59: 6337-43. PMID 26248372 DOI: 10.1128/Aac.01050-15 |
0.443 |
|
| 2015 |
Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 61: S25-31. PMID 26224769 DOI: 10.1093/Cid/Civ427 |
0.501 |
|
| 2015 |
Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 61: S18-24. PMID 26224768 DOI: 10.1093/Cid/Civ426 |
0.46 |
|
| 2015 |
Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 61: S10-7. PMID 26224767 DOI: 10.1093/Cid/Civ425 |
0.453 |
|
| 2015 |
Pasipanodya J, Srivastava S, Gumbo T. Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis. The Journal of Infectious Diseases. 212: 166-7. PMID 25649174 DOI: 10.1093/Infdis/Jiv068 |
0.441 |
|
| 2015 |
Srivastava S, Pasipanodya J, Sherman CM, Meek C, Leff R, Gumbo T. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. Antimicrobial Agents and Chemotherapy. 59: 2273-9. PMID 25645830 DOI: 10.1128/Aac.04441-14 |
0.36 |
|
| 2015 |
Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrobial Agents and Chemotherapy. 59: 38-45. PMID 25313213 DOI: 10.1128/Aac.03931-14 |
0.416 |
|
| 2015 |
Pasipanodya JG, Srivastava S, Gumbo T. Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. The Journal of Antimicrobial Chemotherapy. 70: 320-1. PMID 25182065 DOI: 10.1093/Jac/Dku345 |
0.376 |
|
| 2014 |
Pasipanodya JG, Srivastava S, Gumbo T. Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis. The Pediatric Infectious Disease Journal. 33: 1205. PMID 25361414 DOI: 10.1097/Inf.0000000000000436 |
0.467 |
|
| 2014 |
Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrobial Agents and Chemotherapy. 58: 6111-5. PMID 25092691 DOI: 10.1128/Aac.03549-14 |
0.408 |
|
| 2014 |
Pusch T, Pasipanodya JG, Hall RG, Gumbo T. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. Bmc Infectious Diseases. 14: 115. PMID 24580808 DOI: 10.1186/1471-2334-14-115 |
0.487 |
|
| 2013 |
Musuka S, Srivastava S, Dona CWS, Meek C, Leff R, Pasipanodya J, Gumbo T. Thioridazine Pharmacokinetic-Pharmacodynamic Parameters “Wobble” during Treatment of Tuberculosis: a Theoretical Basis for Shorter-Duration Curative Monotherapy with Congeners Antimicrobial Agents and Chemotherapy. 57: 5870-5877. PMID 24041886 DOI: 10.1128/Aac.00829-13 |
0.453 |
|
| 2013 |
Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. The Journal of Infectious Diseases. 208: 1464-73. PMID 23901086 DOI: 10.1093/Infdis/Jit352 |
0.47 |
|
| 2013 |
Pasipanodya JG, Moonan PK, Vecino E, Miller TL, Fernandez M, Slocum P, Drewyer G, Weis SE. Allopatric tuberculosis host-pathogen relationships are associated with greater pulmonary impairment. Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases. 16: 433-40. PMID 23501297 DOI: 10.1016/J.Meegid.2013.02.015 |
0.621 |
|
| 2013 |
Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 21-31. PMID 23487389 DOI: 10.1093/Cid/Cit167 |
0.401 |
|
| 2013 |
Pasipanodya JG, Gumbo T. Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. American Journal of Respiratory and Critical Care Medicine. 187: 554-5. PMID 23457368 DOI: 10.1164/Ajrccm.187.5.554 |
0.326 |
|
| 2013 |
Pasipanodya J, Srivastava S, Gumbo T. New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates. Antimicrobial Agents and Chemotherapy. 56: 5428. PMID 22972799 DOI: 10.1128/Aac.00976-12 |
0.423 |
|
| 2012 |
Pasipanodya JG, Srivastava S, Gumbo T. Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 16: 706-7. PMID 22507940 DOI: 10.5588/Ijtld.11.0850 |
0.409 |
|
| 2012 |
Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 169-77. PMID 22467670 DOI: 10.1093/Cid/Cis353 |
0.374 |
|
| 2012 |
Pasipanodya JG, Vecino E, Miller TL, Munguia G, Drewyer G, Fernandez M, Slocum P, Weis SE. Non-hispanic whites have higher risk for pulmonary impairment from pulmonary tuberculosis. Bmc Public Health. 12: 119. PMID 22325005 DOI: 10.1186/1471-2458-12-119 |
0.662 |
|
| 2011 |
Vecino M, Pasipanodya JG, Slocum P, Bae S, Munguia G, Miller T, Fernandez M, Drewyer G, Weis SE. Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. Journal of Infection and Public Health. 4: 244-52. PMID 22118719 DOI: 10.1016/J.Jiph.2011.08.005 |
0.69 |
|
| 2011 |
Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. The Journal of Infectious Diseases. 204: 1951-9. PMID 22021624 DOI: 10.1093/Infdis/Jir658 |
0.528 |
|
| 2011 |
Angeby K, Giske CG, Juréen P, Schön T, Pasipanodya JG, Gumbo T. Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 55: 4492-3; author reply. PMID 21849570 DOI: 10.1128/Aac.00232-11 |
0.386 |
|
| 2011 |
Pasipanodya JG, Gumbo T. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Current Opinion in Pharmacology. 11: 457-63. PMID 21807559 DOI: 10.1016/J.Coph.2011.07.001 |
0.477 |
|
| 2011 |
Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrobial Agents and Chemotherapy. 55: 539-45. PMID 21098246 DOI: 10.1128/Aac.00763-10 |
0.372 |
|
| 2010 |
Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrobial Agents and Chemotherapy. 55: 24-34. PMID 20937778 DOI: 10.1128/Aac.00749-10 |
0.348 |
|
| 2010 |
Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. Bmc Public Health. 10: 259. PMID 20482835 DOI: 10.1186/1471-2458-10-259 |
0.757 |
|
| 2010 |
Shaw JET, Pasipanodya JG, Gumbo T. Meningeal tuberculosis: High long-term mortality despite standard therapy Medicine. 89: 189-195. PMID 20453606 DOI: 10.1097/Md.0B013E3181Df9070 |
0.368 |
|
| 2010 |
Weis SE, Pasipanodya JG. Measuring health-related quality of life in tuberculosis: a systemic review--response. Health and Quality of Life Outcomes. 8: 7; author reply 6. PMID 20085632 DOI: 10.1186/1477-7525-8-7 |
0.394 |
|
| 2010 |
Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Drewyer G, Weis SE. The societal cost of tuberculosis: Tarrant County, Texas, 2002. Annals of Epidemiology. 20: 1-7. PMID 20006270 DOI: 10.1016/J.Annepidem.2009.09.004 |
0.726 |
|
| 2009 |
Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. Plos One. 4: e5080. PMID 19352424 DOI: 10.1371/Journal.Pone.0005080 |
0.764 |
|
| 2007 |
Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE. Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest. 132: 1591-8. PMID 17890471 DOI: 10.1378/Chest.07-0755 |
0.655 |
|
| 2007 |
Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 131: 1817-24. PMID 17400690 DOI: 10.1378/Chest.06-2949 |
0.68 |
|
| Show low-probability matches. |